axinn



LESS THAN 1 MIN READ

April 22, 2024, 3:57 PM By: Matthew S. Murphy, Thomas K. Hedemann

Two weeks ago we discussed Vanda Pharmaceuticals' ambitious cert petition asking the Supreme Court to discontinue the "reasonable expectation of success" standard for patent obviousness that for decades has been a mainstay of patent law.

Vanda argued that the Court should instead adopt a "predictable results" standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda's petition, leaving the obviousness standard unchanged.



Related People



Matthew S. Murphy



Thomas K. Hedemann

Related Services

Intellectual Property

To subscribe to our publications, click here.

TAGS

generics

News & Insights

- Consumer Brands CPG Legal Forum 2026
 SPEAKING ENGAGEMENT
- NBA CLS 39th Annual Corporate Counsel Conference SPONSORSHIP ANTITRUST
- New Frontiers of Antitrust 16th Annual International Conference of Concurrences Review
 SPEAKING ENGAGEMENT ANTITRUST
- GCR Live Global: Navigating the Future of Antitrust 2026
 SPEAKING ENGAGEMENT ANTITRUST
- Why Should I Care About Property Controls?
 SPEAKING ENGAGEMENT ANTITRUST
- What's the Score, Your Honor? Conversation With Judge Richard Boulware PODCAST
- LCA Renaissance Symposium XIX 2025
 SPEAKING ENGAGEMENT ANTITRUST
- Stakeholders 25th Annual CYOC Career Development Conference SPONSORSHIP ANTITRUST

- Japan Competition Law Update

 AXINN VIEWPOINTS ANTITRUST
- California's Crackdown on Algorithmic Pricing

 AXINN VIEWPOINTS ANTITRUST

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved